Related Experiment Video
Updated: May 10, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Approaches to immunosuppression in Behçet's disease
Cloé Comarmond1, Bertrand Wechsler, Patrice Cacoub
1Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Médecine Interne 2, Université Pierre et Marie Curie-Paris VI, 83 Boulevard de l'Hôpital, 75013 Paris, France.
Immunotherapy
|July 9, 2013
Summary
Behçet
Area of Science:
- Rheumatology and Immunology
- Systemic Vasculitis Research
Background:
- Behçet's disease (BD) is a systemic vasculitis with diverse clinical manifestations.
- Management varies from topical treatments to aggressive immunosuppression based on organ involvement.
- Refractory cases and organ damage remain significant challenges in BD treatment.
Purpose of the Study:
- To review the current understanding of Behçet's disease pathogenesis.
- To explore emerging therapeutic strategies targeting specific pathways in BD.
- To discuss the potential of novel immunomodulatory drugs for refractory cases.
Main Methods:
- Literature review of Behçet's disease management and pathogenesis.
- Analysis of current and emerging therapeutic approaches.
- Discussion of future directions in targeted immunosuppression for BD.
Main Results:
- Current treatments include colchicine, NSAIDs, corticosteroids, and immunosuppressants.
- Severe BD manifestations often require aggressive immunosuppressive therapy.
- Understanding pathogenic mechanisms is leading to novel targeted therapies.
Conclusions:
- Behçet's disease requires tailored treatment based on clinical presentation.
- Emerging immunomodulatory drugs offer targeted approaches for specific pathogenic pathways.
- Novel therapies hold promise for improving outcomes in refractory Behçet's disease.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:40Cell-mediated Immune Responses
Overview